staurosporine aglycone has been researched along with Psoriasis in 1 studies
staurosporine aglycone: metabolite from culture broth of Nocardiopsis sp.; a neurotrophin antag; inhibits BDNF TrkB receptor
Psoriasis: A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raychaudhuri, SP | 1 |
| Sanyal, M | 1 |
| Weltman, H | 1 |
| Kundu-Raychaudhuri, S | 1 |
1 other study available for staurosporine aglycone and Psoriasis
| Article | Year |
|---|---|
K252a, a high-affinity nerve growth factor receptor blocker, improves psoriasis: an in vivo study using the severe combined immunodeficient mouse-human skin model.
Topics: Animals; Carbazoles; Cell Division; Disease Models, Animal; Humans; Indole Alkaloids; Keratinocytes; | 2004 |